MENXF yields 2000000.00% · JNJ yields 2.13%● Live data
📍 MENXF pulled ahead of the other in Year 1
Combined, MENXF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MENXF + JNJ for your $10,000?
Memex Inc. develops, commercializes, and manufactures a suite of products for its customers in the discrete manufacturing and aerospace sectors worldwide. The company primarily offers MERLIN Tempus, a software-driven industrial Internet of Things communications platform that provides manufacturing productivity metrics, including overall equipment effectiveness in real time. Its MERLIN Tempus measures and analyzes manufacturing and production performance, and provides its users with real-time insights on operational efficiency. The company also provides MERLIN Tempus Enterprise Edition for enhancing the value of time with enterprise resource planning connectivity and job scheduling; MERLIN financial Overall Equipment Effectiveness (FOEE), which enables factory organizations to link their shop floor performance to actual profit dollars; MERLIN Continuous Improvement (CI) Fast-track services, a nine-step implementation process; and MERLIN Operator Portal, a Windows based human machine interface (HMI) that provides operators with a live window into what information is being collected from the machines in real-time. In addition, the company provides MERLIN Enterprise Resource Planning connector, a bi-synchronous interface; MERLIN OPTime to assess, measure, identify, and optimize data-driven manufacturing; and SCANGun, a bar code scanner. Further, it offers IIoT hardware solutions, including MERLIN MTC-One that incorporate sensor-based process-driven data; MTConnect hardware adapter, which enables machine tool to communicate critical operational information using the MTConnect standard protocol; software adapters; and DNC memory upgrade products. Memex Inc. was founded in 1992 and is headquartered in Burlington, Canada.
Full MENXF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.